Bank of New York Mellon’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-502,898
| Closed | -$86.5M | – | 4703 |
|
|
2021
Q3 | $86.5M | Sell |
502,898
-1,435
| -0.3% | -$188K | 0.02% | 762 |
|
|
2021
Q2 | $63.3M | Sell |
504,333
-39,313
| -7% | -$4.96M | 0.01% | 985 |
|
|
2021
Q1 | $73.7M | Buy |
543,646
+60,782
| +13% | +$7.85M | 0.02% | 861 |
|
|
2020
Q4 | $61.8M | Buy |
482,864
+26,082
| +6% | +$3.06M | 0.01% | 922 |
|
|
2020
Q3 | $51.4M | Buy |
456,782
+128,393
| +39% | +$12.8M | 0.01% | 902 |
|
|
2020
Q2 | $31.3M | Sell |
328,389
-30,516
| -9% | -$2.94M | 0.01% | 1163 |
|
|
2020
Q1 | $32.3M | Sell |
358,905
-378,788
| -51% | -$29.4M | 0.01% | 999 |
|
|
2019
Q4 | $39.1M | Buy |
737,693
+1,231
| +0.2% | +$56.1K | 0.01% | 1133 |
|
|
2019
Q3 | $29.1M | Buy |
736,462
+259,446
| +54% | +$11.3M | 0.01% | 1291 |
|
|
2019
Q2 | $19.6M | Sell |
477,016
-6,795
| -1% | -$281K | 0.01% | 1577 |
|
|
2019
Q1 | $22.5M | Buy |
483,811
+44,167
| +10% | +$1.94M | 0.01% | 1481 |
|
|
2018
Q4 | $19.1M | Buy |
439,644
+250,254
| +132% | +$12.5M | 0.01% | 1498 |
|
|
2018
Q3 | $10.8M | Buy |
189,390
+18,286
| +11% | +$899K | ﹤0.01% | 1981 |
|
|
2018
Q2 | $8.3M | Buy |
171,104
+5,028
| +3% | +$183K | ﹤0.01% | 2118 |
|
|
2018
Q1 | $6.49M | Buy |
166,076
+1,117
| +0.7% | +$47.5K | ﹤0.01% | 2210 |
|
|
2017
Q4 | $7M | Sell |
164,959
-686
| -0.4% | -$25.7K | ﹤0.01% | 2190 |
|
|
2017
Q3 | $6.18M | Buy |
165,645
+27,084
| +20% | +$940K | ﹤0.01% | 2241 |
|
|
2017
Q2 | $4.21M | Buy |
138,561
+18,269
| +15% | +$529K | ﹤0.01% | 2408 |
|
|
2017
Q1 | $3.19M | Sell |
120,292
-15,329
| -11% | -$404K | ﹤0.01% | 2573 |
|
|
2016
Q4 | $3.46M | Buy |
135,621
+3,760
| +3% | +$119K | ﹤0.01% | 2527 |
|
|
2016
Q3 | $4.77M | Sell |
131,861
-5,828
| -4% | -$193K | ﹤0.01% | 2259 |
|
|
2016
Q2 | $4.68M | Buy |
137,689
+5,966
| +5% | +$194K | ﹤0.01% | 2240 |
|
|
2016
Q1 | $3.48M | Buy |
131,723
+24,578
| +23% | +$715K | ﹤0.01% | 2373 |
|
|
2015
Q4 | $5.22M | Buy |
107,145
+10,615
| +11% | +$382K | ﹤0.01% | 2188 |
|
|
2015
Q3 | $2.4M | Buy |
96,530
+3,171
| +3% | +$95.3K | ﹤0.01% | 2625 |
|
|
2015
Q2 | $2.95M | Buy |
93,359
+21,327
| +30% | +$688K | ﹤0.01% | 2666 |
|
|
2015
Q1 | $2.74M | Buy |
72,032
+2,011
| +3% | +$80K | ﹤0.01% | 2653 |
|
|
2014
Q4 | $2.73M | Buy |
70,021
+2,361
| +3% | +$82.3K | ﹤0.01% | 2648 |
|
|
2014
Q3 | $2.05M | Buy |
67,660
+7,008
| +12% | +$197K | ﹤0.01% | 2864 |
|
|
2014
Q2 | $2.06M | Buy |
60,652
+27,857
| +85% | +$932K | ﹤0.01% | 2889 |
|
|
2014
Q1 | $1.13M | Buy |
32,795
+10,428
| +47% | +$471K | ﹤0.01% | 3207 |
|
|
2013
Q4 | $886K | Buy |
+22,367
| New | +$540K | ﹤0.01% | 3360 |
|
Bank of New York Mellon's XLRN Position: Q4 2021 in Review
Bank of New York Mellon sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 502,898 shares — an estimated $86.5M sold.
Bank of New York Mellon first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $86.5M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Bank of New York Mellon reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Bank of New York Mellon sold 502,898 Acceleron Pharma shares in Q4 2021, an estimated $86.5M.
- Bank of New York Mellon first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Bank of New York Mellon's Acceleron Pharma position peaked at $86.5M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Bank of New York Mellon's 13F filing for Q4 2021, filed 11 Feb 2022.